ABCG2 mRNA expression determined by QPCR in CD138 selected human plasma cells from bone marrow aspirates obtained from patients with multiple myeloma prior to and during high-dose chemotherapy, and at the time of relapse
. | . | ABCG2 mRNA expression/cell† . | . | . | ||
|---|---|---|---|---|---|---|
| Patient . | Dose level MTV* . | Before HDC . | During HDC . | Relapse from HDC . | ||
| 1 | 1 | 143.5 | 421.3 | 282.5 | ||
| 2 | 1 | 7.4 | 12.3 | 29.6 | ||
| 3 | 1 | 87.9 | 29.8 | ND | ||
| 4 | 1 | 140.8 | 67.5 | 38.9 | ||
| 5 | 1 | 20.6 | 49.0 | ND | ||
| 6 | 1 | 2.4 | 24.5 | 0.1 | ||
| 7 | 1 | 37.6 | ND | 40.4 | ||
| 8 | 2 | 8.6 | 18.7 | 12.4 | ||
| 9 | 2 | 8.7 | 111.8 | 62.3 | ||
| 10 | 3 | 33.2 | 86.4 | 422.6 | ||
| 11 | 3 | 30.0 | 35.6 | 38.9 | ||
| 12 | 3 | 253.2 | 154.7 | ND | ||
| 13 | 3 | 9.5 | ND | 44.1 | ||
| 14 | 3 | 10.2 | ND | 67.7 | ||
| 15 | 4 | 193.8 | 122.3 | 1234.8 | ||
| 16 | 4 | 882.6 | 1133.4 | ND | ||
| 17 | 4 | 443.9 | 1908.0 | ND | ||
| 18 | 4 | 202.8 | 1791.1 | ND | ||
| 19 | 4 | 813.6 | 1595.6 | ND | ||
| 20 | 4 | 446.0 | 852.5 | ND | ||
| 21 | 4 | 45.9 | 14.3 | ND | ||
| 22 | 4 | 342.2 | 164.0 | ND | ||
| 23 | 4 | 1604.1 | 1877.3 | ND | ||
| 24 | 4 | 558.1 | 316.2 | ND | ||
| 25 | 4 | 42.9 | 97.4 | ND | ||
| 26 | 4 | 176.3 | ND | 354.1 | ||
| 27 | 4 | 100.2 | ND | 140.6 | ||
| 28 | 5 | 44.2 | 183.1 | ND | ||
| 29 | 5 | 78.6 | 146.6 | ND | ||
| 30 | 5 | 53.9 | 31.6 | 103.0 | ||
| 31 | 5 | 24.7 | 2893.8 | 238.2 | ||
. | . | ABCG2 mRNA expression/cell† . | . | . | ||
|---|---|---|---|---|---|---|
| Patient . | Dose level MTV* . | Before HDC . | During HDC . | Relapse from HDC . | ||
| 1 | 1 | 143.5 | 421.3 | 282.5 | ||
| 2 | 1 | 7.4 | 12.3 | 29.6 | ||
| 3 | 1 | 87.9 | 29.8 | ND | ||
| 4 | 1 | 140.8 | 67.5 | 38.9 | ||
| 5 | 1 | 20.6 | 49.0 | ND | ||
| 6 | 1 | 2.4 | 24.5 | 0.1 | ||
| 7 | 1 | 37.6 | ND | 40.4 | ||
| 8 | 2 | 8.6 | 18.7 | 12.4 | ||
| 9 | 2 | 8.7 | 111.8 | 62.3 | ||
| 10 | 3 | 33.2 | 86.4 | 422.6 | ||
| 11 | 3 | 30.0 | 35.6 | 38.9 | ||
| 12 | 3 | 253.2 | 154.7 | ND | ||
| 13 | 3 | 9.5 | ND | 44.1 | ||
| 14 | 3 | 10.2 | ND | 67.7 | ||
| 15 | 4 | 193.8 | 122.3 | 1234.8 | ||
| 16 | 4 | 882.6 | 1133.4 | ND | ||
| 17 | 4 | 443.9 | 1908.0 | ND | ||
| 18 | 4 | 202.8 | 1791.1 | ND | ||
| 19 | 4 | 813.6 | 1595.6 | ND | ||
| 20 | 4 | 446.0 | 852.5 | ND | ||
| 21 | 4 | 45.9 | 14.3 | ND | ||
| 22 | 4 | 342.2 | 164.0 | ND | ||
| 23 | 4 | 1604.1 | 1877.3 | ND | ||
| 24 | 4 | 558.1 | 316.2 | ND | ||
| 25 | 4 | 42.9 | 97.4 | ND | ||
| 26 | 4 | 176.3 | ND | 354.1 | ||
| 27 | 4 | 100.2 | ND | 140.6 | ||
| 28 | 5 | 44.2 | 183.1 | ND | ||
| 29 | 5 | 78.6 | 146.6 | ND | ||
| 30 | 5 | 53.9 | 31.6 | 103.0 | ||
| 31 | 5 | 24.7 | 2893.8 | 238.2 | ||
The QPCR was repeated twice for each patient, and the value is the geometric mean of those 2 observations (see “Real-time QPCR”).
MTV indicates melphalan + topotecan + VP-16 phosphate; HDC, high-dose chemotherapy; ND, not done either because of insufficient CD138 cells isolated or because the patient has not relapsed from HDC.
Patients on dose level 1 received 3 days of melphalan followed by 2 days of VP-16 phosphate. Those on dose levels 2 to 5 received 3 days of melphalan followed immediately by dose-escalated topotecan each day for 3 days, followed by 2 days of VP-16 phosphate.
The expression of ABCG2 is normalized to that of GAPDH.